NeurologyLive® Friday 5 — August 2, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Aligning Educational Courses With Trends in Neurology

In episode 3 of the "Previewing the 2024 AUPN Annual Meeting" roundtable discussion, John England, MD, and Lisa Merlin, MD, commented on the significant changes to neurology over the years and how education aligns with the latest in treatments advancements and understanding of neurological disorders.

2: Potential Cognitive Benefits of Using GLP-1 Analogs for Alzheimer Disease Treatment: Paul Edison, MD, PhD

The professor of neuroscience at Imperial College London talked about results from a study assessing a glucagon-like peptide-1 analogue, liraglutide, in patients with Alzheimer disease. [WATCH TIME: 5 minutes]

3: Exploring Wildfire Smoke Exposure and Risk of Dementia in an Older Patient Population: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPH

A duo of experts talked about the association of long-term exposure to fine particulate matter from wildfires and the increased risk of dementia among older adults. [WATCH TIME: 7 minutes]

4: NeuroVoices: Soeren Mattke, MD, DSc, on Utilizing Blood Tests to Reduce Wait Times and Improve Diagnosis in Alzheimer Disease

The director of the Brain Health Observatory at the University of Southern California discussed the potential impact of Alzheimer disease blood tests on reducing clinic wait times and improving the diagnostic process in primary care.

5: Understanding the Therapeutic Potential of Lomecel-B for Alzheimer Disease: Joshua Hare, MD

The co-founder and chief science officer at Longeveron provided commentary on the therapeutic potential of Lomecel-B, a living cell product in development for patients with Alzheimer disease. [WATCH TIME: 3 minutes]